Perrigo (PRGO) is drawing investor attention after recent share price moves that left the stock at US$14.27 at the last close. The company’s mixed return profile and current valuation metrics are now under closer review.

Perrigo’s recent 41.43% 1 month share price return and 32.13% 3 month share price return signal building short term momentum, although the 1 year total shareholder return is still down 34.86%.

If you are looking beyond Perrigo and want more ideas in health related themes, it could be worth checking a screener focused on 40 healthcare AI stocks

Perrigo’s consumer health business has real scale and global reach, yet the share price jump to US$14.27 raises a different issue. Are you now paying a fair price for that quality, or still getting a discount?

Most Popular Narrative: 13.5% Undervalued

The most followed narrative on Perrigo currently anchors on a fair value of $16.50, which sits above the latest close at $14.27. That narrative leans heavily on how earnings could recover from today’s loss making base.

Analysts expect earnings to reach $73.4 million (and earnings per share of $0.52) by about June 2029, up from $1.8 billion of losses today. In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 41.9x on those 2029 earnings, up from 0.8x today.

Want to understand why Perrigo’s fair value assumes a sharp earnings swing and a premium future earnings multiple? The narrative leans on specific margin repair, revenue stability and share count expectations that are not obvious from the current headline numbers.

Result: Fair Value of $16.50 (UNDERVALUED)

However, the Perrigo narrative can still be challenged if weak category demand persists, or if infant formula and OTC competition continue to pressure pricing and market share.

Next Steps

With the Perrigo narrative split between concerns and optimism, this is a moment to look through the numbers yourself and move quickly to form an independent view using the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Perrigo?

If Perrigo has sharpened your interest in new opportunities, do not stop here. Use the Simply Wall Street Screener to uncover other stocks that might fit your goals.

• Target reliable income streams by scanning for companies in the 12 dividend fortresses that may suit a more income focused approach.
• Spot potential bargains early by searching across the screener containing 18 high quality undiscovered gems before they attract wider attention.
• Prioritise resilience by filtering for companies in the 74 resilient stocks with low risk scores that align with a more cautious style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.